Patent US5010073A successfully refreshed from Google Patents.
US5010073A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of liposomes as carriers for metalloporphyrins
Assignee: Rockefeller University
•
Filing: 1990-02-26
•
Granted: 1991-04-23
•
Expires: 2010-02-26
Abstract
Abstract Pharmaceutical copositions comprising liposomal metalloporphyrins are provided for parenteral administration to mammals, including humans. These liposomal metalloporphyrins selectively target the spleen and markedly inhibit the heme oxygenase activity therein. A method is also provided for intravenous administration of these compositions to mammals to selectively target the spleen.
Inventors
- 👤 Attallah Kappas
- 👤 George S. Drummond
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 15:09
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/40; A61K9/00; A61K9/10; A61K9/127; A61P; A61P43/00; A61P7/00; A61P7/06
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
26 words
A pharmaceutical composition for improved inhibition of heme oxygenase activity in mammals comprising a liposomal metalloporphyrin, the metalloporphyrin component of which is a heme oxygenase inhibitor.
Claim 2
Dependent Claim
26 words
A pharmaceutical composition for improved inhibition of heme oxygenase activity in mammals comprising a liposomal metalloporphyrin, the metalloporphyrin component of which is a heme oxygenase inhibitor.
Claim 3
Dependent Claim
28 words
A composition as in claim 1 wherein said metalloporphyrin is selected from the group consisting of tin, chromium, zinc and manganese protoporphyrin, mesoporphyrin and diiododeuteroporphyrin, and mixtures thereof.
Claim 4
Dependent Claim
12 words
A composition as in claim 1 further comprising a pharmaceutically acceptable carrier.
Claim 5
Dependent Claim
17 words
A composition as in claim 1 wherein said metalloporphyrin is tin protoporphyrin, tin mesoporphyrin or tin diiododeuteroporphyrin.
Claim 6
Dependent Claim
12 words
A composition as in claim 4 further including a pharmaceutically acceptable carrier.
Claim 7
Dependent Claim
19 words
A composition as in claim 1 in dosage unit form containing from about 0.07 to about 46 mg/dosage unit.
Claim 8
Dependent Claim
19 words
A composition as in claim 2 in dosage unit form containing from about 0.07 to about 46 mg/dosage unit.
Claim 9
Dependent Claim
19 words
A composition as in claim 3 in dosage unit form containing from about 0.07 to about 46 mg/dosage unit.
Claim 10
Dependent Claim
19 words
A composition as in claim 4 in dosage unit form containing from about 0.07 to about 46 mg/dosage unit.
Claim 11
Independent Claim
40 words
A method of improving the inhibition of heme oxygenase activity in mammals in need of such inhibition which comprises intravenous administration of liposomal metalloporphyrin in an amount sufficient to effect such inhibition, wherein the metalloporphyrin is a heme oxygenase inhibitor.
Claim 12
Independent Claim
40 words
A method of improving the inhibition of heme oxygenase activity in mammals in need of such inhibition which comprises intravenous administration of liposomal metalloporphyrin in an amount sufficient to effect such inhibition, wherein the metalloporphyrin is a heme oxygenase inhibitor.
Claim 13
Dependent Claim
28 words
A method as in claim 10 wherein said metalloporphyrin is selected from the group consisting of tin, chromium, zinc and manganese protoporphyrin, mesoporphyrin and diiododeuteroporphyrin and mixtures thereof.
Claim 14
Dependent Claim
15 words
A method as in claim 10 wherein said metalloporphyrin is in a pharmaceutically acceptable carrier.
Claim 15
Dependent Claim
16 words
A method as in claim 10 wherein metalloporphyrin is tin protporphyrin, tin mesoporphyrin and tin diiododeuteroporphyrin.
Claim 16
Dependent Claim
15 words
A method as in claim 13 wherein said metalloporphyrin is in a pharmaceutically acceptable carrier.
Claim 17
Dependent Claim
23 words
A method as in claim 10 wherein said metalloporphyrin is a dosage unit form containing from about 0.07 to about 46 mg/dosage unit.
Claim 18
Dependent Claim
23 words
A method as in claim 11 wherein said metalloporphyrin is in dosage unit form containing from about 0.07 to about 46 mg/dosage unit.
Claim 19
Dependent Claim
23 words
A method as in claim 12 wherein said metalloporphyrin is in dosage unit form containing from about 0.07 to about 46 mg/dosage unit.
Claim 20
Dependent Claim
23 words
A method as in claim 13 wherein said metalloporphyrin is in dosage unit form containing from about 0.07 to about 46 mg/dosage unit.
Claim 21
Dependent Claim
23 words
A method as in claim 14 wherein said metalloporphyrin is in dosage unit form containing from about 0.07 to about 46 mg/dosage unit.
Claim 22
Dependent Claim
21 words
A method as in claim 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 wherein said mammal is human.
References Cited (Backward Citations)
US4684637A
Cited
US4649151A
Cited
US4657902A
Cited
US4692440A
Cited
US4668670A
Cited
US4692439A
Cited
US4699903A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-04-22 | 1994-10-22 | 1995-04-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-04-22 | 1998-10-22 | 1999-04-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-04-22 | 2002-10-22 | 2003-04-23 | $7700.00 | Window Closed / Lapsed |